Phase Ib/II study of BCL-2 inhibitor lisaftoclax (APG-2575) safety and tolerability when administered alone or combined with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor in patients with estrogen receptor-positive (ER plus ) breast cancer or advanced solid tumors

被引：0
|
作者：
Kalinsky, Kevin
Tolcher, Anthony W.
Wang, Shushen
Meric-Bernstam, Funda
Winkler, Robert
Li, Mingyu
Sun, Xuemei
Pan, Wentao
Paudyal, Bishnuhari
Liang, Zhiyan
Lu, Ming
Yang, Dajun
Zhai, Yifan
机构：
[1] Emory Univ, Winship Canc Inst, Glenn Family Breast Ctr, Dept Hematol & Med Oncol, Atlanta, GA USA
[2] Emory Univ, Winship Canc Inst, Breast Med Oncol, Atlanta, GA USA
[3] NEXT Oncol & Texas Oncol, San Antonio, TX USA
[4] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Canc Ctr, Guangzhou, Peoples R China
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[6] Ascentage Pharma Grp Inc, Rockville, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS1122
引用
收藏
页数：1
相关论文
共 50 条
  • [41] TREATMENT OF PREMENOPAUSAL PATIENTS WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCER WITH AN CDK4/6 INHIBITOR COMBINED WITH ENDOCRINE AGENTS: A REAL-WORLD EXPERIENCE
    Kurbacher, Christian Martin
    Fischer, Lotta Ada
    Heinrich, Georg
    Warm, Mathias
    Schott, Alexander
    Kurbacher, A. Tabea
    Kurbacher, Jutta Anna
    Rudlowski, Christian
    BREAST, 2019, 48 : S55 - S56
  • [42] Standard Versus Reduced CDK4/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: An Observational Multicenter Study
    Fedele, Palma
    Landriscina, Matteo
    Moraca, Lucia
    Gadaleta-Caldarola, Arianna
    Cusmai, Antonio
    Giuliani, Francesco
    Chiuri, Vincenzo
    Giotta, Francesco
    Pinto, Antonello
    Mirisola, Valentina
    Gadaleta-Caldarola, Gennaro
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (23)
  • [43] Phase 1 multicenter, open label, dose-escalation study of LEE011, an oral inhibitor of cyclin-dependent kinase 4/6, in patients with advanced solid tumors or lymphomas
    Infante, Jeffrey R.
    Shapiro, Geoffrey I.
    Witteveen, Petronella O.
    Gerecitano, John F.
    Ribrag, Vincent
    Chugh, Rashmi
    Chakraborty, Abhijit
    Matano, Alessandro
    Zhao, Xumei
    Parasuraman, Sudha
    Cassier, Philippe A.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [44] A phase 1 open-label, dose-escalation study of central nervous systempenetrant cyclin-dependent kinase (CDK)4/6 inhibitor PRT3645 in patients with select advanced or metastatic solid tumors
    Patnaik, Amita
    Salkeni, Mohamad A.
    Patel, Manish R.
    Basu-Mallick, Atrayee
    Shepard, Dale
    Lihou, Christine
    Sun, William
    Xavier, Jennifer
    Sahasranaman, Sri
    Sharma, Neelesh
    Hamilton, Erika
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [45] Patient-derived xenografts (PDXs) generated from hormone receptor-positive breast cancer (BC) before and after cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) treatment: Initial findings from the PROMISE study
    Yu, Jia
    Suman, Vera J.
    He, Jun
    Sinnwell, Jason P.
    Moyer, Ann M.
    Qin, Bo
    Gu, Yayun
    Zhang, Huan
    Carter, Jodi M.
    Kalari, Krishna R.
    McMenomy, Brendan P.
    Liu, Minetta C.
    Haddad, Tufia C.
    Ruddy, Kathryn J.
    Couch, Fergus J.
    Moreno-Aspitia, Alvaro
    Northfelt, Donald W.
    Weinshilboum, Richard
    O'Sullivan, Ciara
    Goetz, Matthew P.
    Wang, Liewei
    CANCER RESEARCH, 2022, 82 (04)
  • [46] The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
    Finn, Richard S.
    Crown, John P.
    Lang, Istvan
    Boer, Katalin
    Bondarenko, Igor M.
    Kulyk, Sergey O.
    Ettl, Johannes
    Patel, Ravindranath
    Pinter, Tamas
    Schmidt, Marcus
    Shparyk, Yaroslav
    Thummala, Anu R.
    Voytko, Nataliya L.
    Fowst, Camilla
    Huang, Xin
    Kim, Sindy T.
    Randolph, Sophia
    Slamon, Dennis J.
    LANCET ONCOLOGY, 2015, 16 (01): : 25 - 35
  • [47] A phase I/IIb study of palbociclib (PALBO) plus everolimus (EVE) and exemestane (EXE) in hormone-receptor positive (HR+)/HER2-metastatic breast cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i): Results of the phase II study
    Barroso-Sousa, Romualdo
    Li, Tianyu
    Trippa, Lorenzo
    Rees, Rebecca
    Andrews, Chelsea
    Ferreira, Arlindo R.
    Helvie, Karla
    Partridge, Ann H.
    Overmoyer, Beth
    Winer, Eric P.
    Wagle, Nikhil
    Tolaney, Sara M.
    CANCER RESEARCH, 2020, 80 (04)
  • [48] Treatment options for patients with hormone receptor-positive, HER2-negative advanced-stage breast cancer: maintaining cyclin-dependent kinase 4/6 inhibitors beyond progression
    Horani, Malek
    Abdel-Razeq, Hikmat
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [49] A phase I study of palbociclib (PALBO) plus everolimus (EVE) and exemestane (EXE) in hormone-receptor positive (HR+)/HER2-metastatic breast cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i): safety, tolerability and pharmacokinetic (PK) analysis.
    Barroso-Sousa, Romualdo
    Guo, Hao
    Barry, William Thomas
    Ferreira, Arlindo R.
    Rees, Rebecca
    Winer, Eric P.
    Wagle, Nikhil
    Tolaney, Sara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [50] BYLieve: A phase 2 study of alpelisib with fulvestrant or letrozole for treatment of PIK3CA mutant, hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (aBC) progressing on/after cyclin-dependent kinase (CDK)4/6 inhibitor therapy
    Rugo, Hope S.
    Turner, Nicholas
    Chia, Stephen
    Ciruelos, Eva
    Nienstedt, Carolyn
    Ridolfi, Antonia
    Kong, Oliver
    Sankaran, Banu
    Juric, Dejan
    CANCER RESEARCH, 2018, 78 (04)
12345